- Lexaria
Bioscience Corp. is the only company worldwide with patents issued for
oral delivery of all cannabinoids
- Its
proprietary technology bests traditional methods such as inhalation in
several key ways
- The
company continues to enhance its intellectual property portfolio as it
pursues patents around the world
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a food
biosciences company, has developed a proprietary technology that has
revolutionized the way cannabidiol (CBD) and other non-psychoactive
cannabinoids are delivered into the bloodstream.
Lexaria, the only company worldwide with patents issued for
oral delivery of all cannabinoids, has greatly improved the delivery of
bioactive compounds. While cannabinoids typically enter the bloodstream in
three main ways, each has its limitations. Inhalation is harmful to the lungs;
sub-lingual (under the tongue) consumption carries a bitter taste unless
copiously sweetened; and oral consumption is typically is very slow to act,
often between one and three hours.
As a disruptor in the cannabis industry, Lexaria’s
DehydraTECH drug delivery platform is changing the way cannabinoids enter the
bloodstream through the gastrointestinal tract. Its proprietary technology
promises multiple advantages in cannabinoid edibles. First, it masks the
undesirable taste typically found in cannabinoid edibles, eliminating the need
to add sweetening agents and enabling sugar-free options. Second, it increases
the product’s absorption rate, with absorption occurring at two- to five-times
higher rates than other edibles. Finally, it reduces the time of onset; effects
of the product are felt within 15-20 minutes of consumption rather than the
typical 60-120 minutes. In a March 2016 focus study, subjects ranked Lexaria’s
formulation as the best tasting and most palatable option. They also found it
to deliver the highest-quality THC experience overall.
Some of Lexaria’s featured products have included protein
energy bars; CBD tablets; exotic teas delivering CBD in multiple flavors;
coffee; and TurboCBD capsules, which are described as “high absorption, full
spectrum hemp oil capsules aimed to increase focus and memory while also
reducing stress and fatigue.”
While Lexaria’s groundbreaking technology has set a new
quality standard for other companies to aspire to, the company also takes pride
in its pursuance of a strong intellectual property portfolio. By the end of
2018, the company’s portfolio included 53 patent applications pending in over
40 countries worldwide, as well as 10 patents already granted. Anticipating new
patent awards in 2019 both in the United States and across the world, Lexaria
continues to make inroads into various industries through its research and
development and key business relationships.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
